Chromosome

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Retrieved on: 
Tuesday, April 2, 2024
Press club, B cell, Longevity, TELO, Chromosome, Research, DNA, MD, Skin, Osteoarthritis, Blood, Ageing, Pharmaceutical industry

BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.

Key Points: 
  • Dr. Roizen serves as Telomir’s special advisor on age reversal.
  • The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
  • “Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
  • As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Speech, X chromosome, Brain, Medicine, MECP2, Disease, Laxative, Seizure, Nervous system, Patient, Chromosome, Committee, Knowledge, Constipation, Regulation, EMA, IRIS, Rett syndrome, Male, Intellectual disability, Clinical trial, European, COMP, Safety, European Commission, Marketing, Parent, Syndrome, DSM-IV codes, Anatomical pathology, Pharmaceutical industry

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Key Points: 


Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Retrieved on: 
Friday, March 22, 2024
B cell, Conference, Longevity, National University Health System, TELO, The New York Times, BGCT, Health, Chromosome, Research, DNA, EDT, Laboratory, MD, Skin, Poster, Telomere, Osteoarthritis, Blood, NUHS, Ageing, Pharmaceutical industry

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

Key Points: 
  • The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
  • This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
  • “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Retrieved on: 
Tuesday, March 26, 2024
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Microsoft, Chromosome, Microsoft Research, Survival, Patient, Biomarker, Nature, Cancer, AI, CIN, Human, Medicine, MBA, FRCP, Therapy, CRISPR, Collaboration, Medical imaging

Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.

Key Points: 
  • Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.
  • While CIN is a hallmark of cancer, levels of CIN vary widely across tumor types from being nearly ubiquitous in some to only partially present in others.
  • Volastra’s two KIF18A inhibitors are in parallel Phase 1 clinical trials treating tumor types with near-universally high levels of CIN.
  • We are excited to apply our proprietary precision medicine platform to clinical trials in the rapidly advancing field of KIF18A inhibition.”

Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics

Retrieved on: 
Tuesday, March 26, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Genetics, Partnership, CIN, Medicine, Function, Chromosome, Patient, Neoplasm, Cancer, Disease, CRISPR, Medical imaging

Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).

Key Points: 
  • Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).
  • Function is leveraging its CRISPR-enabled platform to understand disease in unprecedented and patient-specific detail.
  • By moving beyond traditional gene sequencing to measuring gene function, the Volastra and Function teams aim to identify which patients would benefit from treatment with Volastra’s KIF18A inhibitors.
  • CRISPR technology has transformed precision medicine, and we are excited by the potential of Function’s innovative platform to expand the pool of patients that will benefit from KIF18A inhibitors.”

Genomenon Presents Study Identifying 11,000 Gene Disease Relationships Across the Clinical Exome at the ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, ANN, Gene, Comparison, Broad Institute, Genetic testing, Disease, Risk, CALM3, Patient, Chromosome, Virginia High School League, Doctor of Philosophy, NIH, Medicine, Genome, VUS, PLA2G6, Literature, ACMG, Data, CALM, Vaccine

ANN ARBOR, Mich., March 14, 2024 /PRNewswire-PRWeb/ -- Genomenon, a leading genomic intelligence company, presented data at the ACMG Annual Clinical Genetics Meeting today demonstrating how computational indexing of millions of published abstracts and full-text references combined with a systematic literature review can be used to rapidly and accurately characterize gene-disease relationships (GDRs) and to resolve variants of uncertain significance (VUS). The study was completed in less than six months and identified 10,745 germline GDRs and 5,973 germline GDRs with positive associations between a disease and gene. Each GDR is accompanied by well-documented scientific evidence curated by Genomenon's team of genetic scientists. Today's presentation shares a milestone in the company's mission to curate the human genome and understand the pathogenicity of any variant for patient diagnosis and precision medicine development.

Key Points: 
  • The study was completed in less than six months and identified 10,745 germline GDRs and 5,973 germline GDRs with positive associations between a disease and gene.
  • This need is underscored by the fact that the number of VUS's is growing exponentially due to increased genetic testing and sequencing.
  • The study used a literature-based approach that     gathered variants through Genomenon's Mastermind Genomic Intelligence Platform and variant databases.
  • The study demonstrated that there is only a 27% match of genetic variants listed in current databases and those found in the literature.

Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements

Retrieved on: 
Wednesday, March 6, 2024
Engineering, Doctor of Philosophy, CAR7, Research and development, Chromosome, Kite Pharma, CD7, Cell, Risk, MicroRNA, Safety, History, Malignancy, Patient, Development, Partnership, Vaccine

“miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.

Key Points: 
  • “miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.
  • Proof-of-Concept data for miCAR7 was unveiled for the first time at the 7th CAR-TCR Summit in London on February 28th, 2024.
  • In August of 2023, Antion successfully delivered novel gene constructs and a supporting data package for silencing of four relevant targets to Allogene.
  • With a validated technology platform, established operations and a history of fruitful collaboration, Antion is optimally positioned to accelerate its pipeline developments, while leveraging the full potential of its technology through key strategic partnerships with global innovation leaders.

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Retrieved on: 
Tuesday, March 5, 2024
Stem cell, Advisory board, Cleveland Clinic, Regeneration, Food and Drug Administration, Blood, Zinc, MD, FDA, Ageing, Food, Cancer, Overload, Life, B cell, Attention, Chromosome, Joint, Metal, Heart, Longevity, Imagination, Science, TELO, Brain, Pharmaceutical industry

BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

Key Points: 
  • A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures.
  • He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years.
  • Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry.
  • We look forward to his continued contributions to our efforts.”
    To be included in the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024
Rare disease, Therapy, Regenerative Medicine Advanced Therapy, FAP, Concha bullosa, Sulindac, Chemistry, Fast track (FDA), Muscular dystrophy, FDA, Sensation, News, Eflornithine, DMD, Prader–Willi syndrome, BLA, Chromosome, RDEB, PDUFA, Skin, Voyager, PRISM, Duchenne muscular dystrophy, Safety, Neurocrine Biosciences, Rare Disease Day, Genetics, Fatigue, Walking, PWS, Patient, DSM-IV codes, Medicine, Disease, Exosome, FA, CMC, Priority review, Pharmaceutical industry

All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders.

Key Points: 
  • All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders.
  • Today on Rare Disease Day, PRISM MarketView highlights emerging companies working to deliver life changing treatments for those living with rare diseases.
  • RDEB is a severe rare disease characterized by extremely fragile, and extensive blistering and wounds.
  • Capricor is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Nabsys Opens a Distribution Channel for the OhmX™ Platform in Canada

Retrieved on: 
Thursday, March 7, 2024
Chromosome, Geography, HCE, Point, Analyser, EGM, Laboratory, Research, DNA

PROVIDENCE, R.I., March 7, 2024 /PRNewswire/ -- Next generation genomic tools company, Nabsys®, has executed a nonexclusive agreement with Canadian distributor, DMark Biosciences ("DMark"), for sales of its OhmX™ platform.

Key Points: 
  • PROVIDENCE, R.I., March 7, 2024 /PRNewswire/ -- Next generation genomic tools company, Nabsys®, has executed a nonexclusive agreement with Canadian distributor, DMark Biosciences ("DMark"), for sales of its OhmX™ platform.
  • OhmX is Nabsys' first commercially available product and was released in October 2023.
  • DMark will be responsible for distributing both the Nabsys OhmX™ Analyzer and consumables into both public and private research core labs and institutions in the Canadian market.
  • "With growing demand for the OhmX platform in the US, this distribution agreement marks an important step towards establishing a strong global distribution network," Nabsys' Chief Commercial Officer, Justin Bingham, remarked.